A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Study safety of using glutaminase inhibitor in combination with drug (Nivolumab) in patients with renal cell carcinoma and solid tumors
Sponsor: Calithera Bioscienes, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR5054
U.S. Govt. ID: NCT02771626
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this trial is to evaluate the safety of CB-839 in combination with nivolumab for patients with advanced/metastatic clear cell Renal Cell Carcinoma (ccRCC), melanoma, and Non-Small Cell Lung Cancer. CB-839 is a drug designed to stop cancer growth by blocking glutaminase activity. Glutaminase is an enzyme in the body that is overproduced by some cancers and can fuel cancer growth. Nivolumab is a drug that makes cancer cells more vulnerable to attack by working with your bodys own immune system.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Do you have melanoma? Yes No
Have you received a prior immunotherapy for your melanoma? Yes No
Did your disease get worse while you were on the immunotherapy? Yes No
Do you need to take a steroid greater than 10mg a day? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator